Stryker has completed its acquisition of Inari Medical for $80 per share, strengthening its presence in the peripheral vascular market. Inari specializes in venous thromboembolism (VTE) clot removal without thrombolytic drugs, complementing Stryker’s neurovascular business.

The deal was finalized following a cash tender offer that secured 81.69% of Inari’s outstanding shares. Inari is now a wholly owned subsidiary of Stryker, and its stock has been delisted from Nasdaq.